Evommune, Inc. - Common Stock, $0.0001 par value per share (EVMN)

CUSIP: 30054Y107

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 7 signals
Share change
+1,143,265
Put/Call ratio
142%
SEC-reported price per share
$13.29
Number of holders
104
Value change
-$34,339,695
Number of buys
74
Open additional details 1 more signal available
Number of sells
30
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
41,113,388

Security key

30054Y107

Report period

Q2 2026

Institutions

104

Top holders

10

Ownership snapshot

Top reported holders of EVMN - Evommune, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
7. Cooperatief U.a. Lsp
Disclosed value leader
7. Cooperatief U.a. Lsp
Comparable rows
4/15
Latest evidence
31 Mar 2026
3/4/5 13D/G 13F Lead comparable stake: 15% 11 rows are not safely comparable across share classes. 13D/G row: 7. Cooperatief U.a. Lsp Showing 1-6 of 15 holder rows.

Quick read

7. Cooperatief U.a. Lsp leads the comparable SEC ownership view at 15%.

4 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens 7. Cooperatief U.a. Lsp's linked filing trail.
Comparable ownership Top 4
7. Cooperatief U.a. Lsp 15%
Pivotal bioVenture Partners Fund ... 11%
PRICE T ROWE ASSOCIATES INC /MD/ 5.4%
Andera Partners 3.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
7. Cooperatief U.a. Lsp
3/4/5 13D/G
Director, 10%+ Owner · LSP 7 Cooperatieve U.A.
15%
Reported 13D/G · 12 Feb 2026
$147,438,166
5,288,313 shares
— 17 Feb 2026
Pivotal bioVenture Partners Fund I, L.P.
13D/G 3/4/5
Nan Fung Group Holdings Limited · Director, 10%+ Owner
11%
Reported 13D/G · 31 Dec 2025
$69,158,608
3,435,599 shares
$0 31 Dec 2025
PRICE T ROWE ASSOCIATES INC /MD/
13F 13D/G
Company · T. Rowe Price Associates, Inc.
5.4%
Reported 13D/G · 30 Jun 2026
$25,727,000
1,119,021 shares
— 31 Mar 2026
Andera Partners
13F 13D/G
Company
3.9%
Reported 13D/G · 30 Jun 2026
$43,620,352
1,897,362 shares
— 31 Mar 2026
Isabel Verduyn van Weegen
3/4/5
Director, 10%+ Owner
—
denominator unverified
$147,438,166
5,288,313 shares
— 17 Feb 2026
Robert Lorne Hopfner
3/4/5
Director, 10%+ Owner
—
denominator unverified
$63,219,381
3,372,001 shares
+$17,350 19 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
104
Shares
34,570,369
Rows available
104
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
84
Q2 2026 holders
104
Holder diff
20
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .